SCHEMBL6602394

SCHEMBL6602394

O=Cc1ccc(OCc2c(Cl)cccc2Cl)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.57
ALDH1A1 P00352 7/20 0.51
KDM4E B2RXH2 3/20 0.51
L3MBTL1 Q9Y468 1/20 0.50
RAB9A P51151 1/20 0.50
ITGB1 P05556 1/20 0.49
ITGA4 P13612 1/20 0.49
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
MAPT P10636 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
NPSR1 Q6W5P4 1/20 0.44
LMNA P02545 4/20 0.43
TUBB4A P04350 1/20 0.43
TUBB P07437 1/20 0.43
TUBA3C P0DPH7 1/20 0.43
TUBA1B P68363 1/20 0.43
TUBA4A P68366 1/20 0.43
TUBB4B P68371 1/20 0.43
TUBB3 Q13509 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4909005 0.89 SMN1; SMN2 (0.57) SMN1; SMN2ALDH1A1KDM4EL3MBTL1RAB9A
SCHEMBL2208410 0.83 MAOA (0.62) SMN1; SMN2ALDH1A1RAB9AKMT2AMAPT
SCHEMBL3654464 0.83 ALDH1A1 (0.47) SMN1; SMN2ALDH1A1KDM4EL3MBTL1RAB9A
SCHEMBL6974312 0.83 ALDH1A1 (0.51) SMN1; SMN2ALDH1A1KDM4EL3MBTL1RAB9A
SCHEMBL8422956 0.81 NR4A2 (0.60) SMN1; SMN2ALDH1A1KDM4EL3MBTL1RAB9A
SCHEMBL6685478 0.79 ALDH1A1 (0.51) SMN1; SMN2ALDH1A1KDM4EL3MBTL1RAB9A
SCHEMBL7046284 0.79 SMN1; SMN2 (0.56) SMN1; SMN2ALDH1A1KDM4EITGB1ITGA4
SCHEMBL6940065 0.79 ITGB1 (0.57) SMN1; SMN2ALDH1A1KDM4ERAB9AITGB1
SCHEMBL7046280 0.79 SMN1; SMN2 (0.56) SMN1; SMN2ALDH1A1KDM4EITGB1ITGA4
SCHEMBL3659048 0.78 ALDH1A1 (0.49) SMN1; SMN2ALDH1A1KDM4EL3MBTL1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296711-B2 Substituted isoxazole amide compounds as inhibitors of stearoyl-CoA desaturase 1 (SCD1) HOFFMAN-LA ROCHE INC. (US) 2016-03-29 US disclosed
US-20150307463-A1 SUBSTITUTED ISOXAZOLE AMIDE COMPOUNDS AS INHIBITORS OF STEAROYL-COA DESATURASE 1 (SCD1) HOFFMANN-LA ROCHE INC. 2015-10-29 US disclosed
EP-2925751-A1 SUBSTITUTED ISOXAZOLE AMIDE COMPOUNDS AS INHIBITORS OF STEAROYL-COA DESATURASE 1 (SCD1) F. Hoffmann-La Roche AG (CH) 2015-10-07 EP disclosed
WO-2014086704-A1 SUBSTITUTED ISOXAZOLE AMIDE COMPOUNDS AS INHIBITORS OF STEAROYL-COA DESATURASE 1 (SCD1) F. HOFFMANN-LA ROCHE AG (CH) 2014-06-12 WO disclosed
EP-1066316-B1 CINNAMIC ACID DERIVATIVES HAVING CELL ADHESION MODULATING ACTIVITY CELLTECH THERAPEUTICS LTD (GB) 2004-05-12 EP disclosed
US-20030220392-A1 Fatty acid synthase inhibitors SMITHKLINE BEECHAM CORPORATION 2003-11-27 US disclosed
US-6559179-B1 Tinvention relates to the use of compounds as inhibitors of the fatty acid synthase FabH. SMITHKLINE BEECHAM CORPORATION 2003-05-06 US disclosed
EP-1299376-A1 FATTY ACID SYNTHASE INHIBITORS Smithkline Beecham (US) 2003-04-09 EP disclosed
EP-1206463-A4 FATTY ACID SYNTHASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2003-01-29 EP disclosed
EP-1206465-A4 FATTY ACID SYNTHASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2003-01-02 EP disclosed
EP-1206464-A4 FATTY ACID SYNTHASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2002-12-18 EP disclosed
US-6486192-B1 Indole compounds useful for treating bacterial infections SMITHKLINE BEECHAM CORPORATION 2002-11-26 US disclosed
EP-1206463-A1 FATTY ACID SYNTHASE INHIBITORS SmithKline Beecham Corporation (US) 2002-05-22 EP disclosed
EP-1206464-A1 FATTY ACID SYNTHASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-05-22 EP disclosed
EP-1206465-A1 FATTY ACID SYNTHASE INHIBITORS SmithKline Beecham Corporation (US) 2002-05-22 EP disclosed
US-6329362-B1 MODULATION CELL ADHESION THE COMPOUNDS ARE ABLE TO INHIBIT THE BINDING OF ALPHA 4 INTEGRINS TO THEIR LIGANDS AND ARE OF USE IN THE PROPHYLAXIS AND TREATMENT OF IMMUNE OR INFLAMMATORY DISORDERS. CELLTECH THERAPEUTICS LIMITED (GB) 2001-12-11 US disclosed
WO-2001090099-A1 FATTY ACID SYNTHASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO disclosed
WO-2001014364-A1 FATTY ACID SYNTHASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-03-01 WO disclosed
WO-2001014362-A1 FATTY ACID SYNTHASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-03-01 WO disclosed
WO-2001014363-A1 FATTY ACID SYNTHASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220392-A1 Fatty acid synthase inhibitors FASN, FADS1, FADS2 SMN1; SMN2 4708/4885ALDH1A1 985/4885KDM4E 2316/4885
US-20150307463-A1 SUBSTITUTED ISOXAZOLE AMIDE COMPOUNDS AS INHIBITORS OF STEAROYL-COA DESATURASE 1 (SCD1) SCD, SCD5, CPT1A SMN1; SMN2 2050/4885ALDH1A1 245/4885KDM4E 797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.